Insight

Aditya Juloori: Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer

Photo taken from Aditya Juloori/X

Aug 14, 2024, 13:00

Aditya Juloori: Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer

Aditya Juloori, Radiation Oncologist at The University of Chicago Medical Center, shared on X:

“Check out our multi-center phase 2 IIT currently accruing for upfront SBRT added to Durvalumab-based chemoimmunotherapy for the first line treatment of extensive stage SCLC – the DARES trial.”

DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer

Authors: Christine M. Bestvina, Jared H. L. Hara, Theodore Karrison, Benjamen Bowar, Janet Chin, Marina C. Garassino, Sean P. Pitroda, Rajat Thawani, Everett E. Vokes, Gregory Gan, Jun Zhang, Andrew M. Baschnagel, Toby C. Campbell, Steven Chmura and Aditya Juloori.

Source: Aditya Juloori/X

Aditya Juloori cancer DARES trial Durvalumab Durvalumab-based chemoimmunotherapy multi-center trial OncoDaily Oncology SCLC The University of Chicago Medical Center

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Donald Trump: Thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of HHS

Overview of ASCO Breakthrough

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Isabel Mestres: In a world where the fight against cancer knows no borders, collaboration is not optional - it’s essential

Special Coverage